| Literature DB >> 33771601 |
K Steinhauer1, T L Meister2, D Todt3, A Krawczyk4, L Paßvogel5, B Becker6, D Paulmann6, B Bischoff6, M Eggers7, S Pfaender2, F H H Brill6, E Steinmann2.
Abstract
In the ongoing SARS CoV-2 pandemic, effective disinfection measures are needed, and guidance based on the methodological framework of the European Committee for Standardization (CEN) may enable the choice of effective disinfectants on an immediate basis. This study aimed to elucidate whether disinfectants claiming 'virucidal activity against enveloped viruses' as specified in the European Standard EN 14476 as well as in the German Association for the Control of Viral Diseases/Robert Koch Institute (DVV/RKI) guideline are effectively inactivating SARS-CoV-2. Two commercially available formulations for surface disinfection and one formulation for hand disinfection were studied regarding their virucidal activity. Based on the data of this study the enveloped SARS-CoV-2 is at least equally susceptible compared to the standard test virus vaccinia used in the EN 14476 and DVV/RKI guidelines. Thus, chemical disinfectants claiming 'virucidal activity against enveloped viruses' based on the EN 14476 and DVV/RKI guidelines will be an effective choice to target enveloped SARS-CoV-2 as a preventive measure.Entities:
Keywords: Disinfection; EN 14476; SARS-CoV-2; Vaccinia; Virucidal activity
Year: 2021 PMID: 33771601 PMCID: PMC7986349 DOI: 10.1016/j.jhin.2021.03.015
Source DB: PubMed Journal: J Hosp Infect ISSN: 0195-6701 Impact factor: 3.926
Log10 reduction of SARS-CoV-2 titres by three different formulations used for either surface or hand disinfection
| Formulation | Concentration (% v/v) | Contact time (s) | Soiling | Test method | Titre of the SARS-CoV-2 control (log10 TCID50/mL) | Logarithmic reduction factor |
|---|---|---|---|---|---|---|
| A | 20 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥4.02 |
| 80 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥4.02 | |
| B | 20 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥4.02 |
| 20 | 60 | 0.03% BSA | EN 14476 | 6.37 | ≥3.17 | |
| 80 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥4.38 | |
| 80 | 30 | 0.03% BSA | EN 14476 | 6.37 | ≥4.38 | |
| 80 | 60 | 0.03% BSA | EN 14476 | 6.37 | ≥2.17 | |
| C | 20 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥4.02 |
| 20 | 30 | 0.03% BSA | EN 14476 | 6.22 | ≥3.02 | |
| 80 | 15 | 0.03% BSA | EN 14476 | 6.22 | ≥2.02 | |
| 80 | 30 | 0.03% BSA | EN 14476 | 6.22 | ≥4.38 |
TCID50, tissue culture infectious dose 50%; BSA, bovine serum albumin.
Pre-screening experiments: data are based on N = 1; due to cytotoxicity of the tested substance the detection limit did not allow detection of higher virus reduction.
Reduction factor value was acquired by large volume plating.
Log10 reduction of vaccinia virus titres by three different formulations used for either surface or hand disinfection
| Formulation | Concentration (% v/v) | Contact time (s) | Soiling | Test method | Titre of the vaccinia virus control (log10 TCID50/mL) | Logarithmic reduction factor vaccinia virus |
|---|---|---|---|---|---|---|
| A | 20 | 15 | 10% FCS | DVV/RKI guideline | 7.44 | 0 |
| 90 | 15 | 10% FCS | DVV/RKI guideline | 7.44 | ≥4.25 | |
| B | 80 | 30 | 10% FCS | DVV/RKI guideline | 7.82 | ≥4.32 |
| 80 | 60 | 10% FCS | DVV/RKI guideline | 7.82 | ≥4.51 | |
| C | 20 | 15 | 0.03% BSA | EN 14476 | 7.67 | 0.17 |
| 80 | 15 | 0.03% BSA | EN 14476 | 7.67 | ≥4.19 |
TCID50, tissue culture infectious dose 50%; FCS, fetal calf serum; DVV/RKI, German Association for the Control of Viral Diseases/Robert Koch Institute; BSA, bovine serum albumin.
All experiments were carried out as independent experiments and data presented are based on at least two experiments.
Highest test concentration for ready-to-use formulations as specified in the DVV/RKI guideline.
Test virus used: vaccinia virus strain modified virus Ankara (MVA) ATCC VR-1508.
Test virus used: vaccinia virus strain Elstree.